Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Herceptin
Pharma
Jazz’s Ziihera nets FDA nod in first-line HER2+ stomach cancer
Jefferies analysts recently put Ziihera’s peak sales at $1.5 billion in gastroesophageal adenocarcinoma alone.
Angus Liu
Aug 25, 2026 11:06am
Jazz touts Ziihera as HER2 agent of choice in stomach cancer
Jan 6, 2026 3:25pm
FDA approves AZ/Daiichi's Enhertu in 1st-line breast cancer
Dec 15, 2025 4:15pm
Roche bolsters Perjeta's case with ten-year breast cancer data
May 13, 2025 11:23am
Roche settles UPenn patent lawsuit over breast cancer drugs
Mar 14, 2025 3:00pm
Merck's Keytruda mostly won out at ESMO, with one notable miss
Oct 24, 2023 9:05am
